Makoto Ueno

Kanagawa Prefectural Hospital Organization

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial”.

Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial

Nature Medicine(2024)10.1038/s41591-024-02934-7

N/A

0.637DataRank · unranked

69 citations

Silvia Damian, Muhammad Furqan, Jesús García-Donás, Hiroo Imai, Antoîne Italiano +10 more

Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer

Nature Communications(2020)10.1038/s41467-020-16711-w

N/A

0.621DataRank · unranked

62 citations

Masahiro Nakatochi, Yasuyuki Hosono, Hidemi Ito, Yoichiro Kamatani, Akihito Inoko +81 more

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers

Hepatology(2023)10.1097/hep.0000000000000365

N/A

0.590DataRank · unranked

50 citations

Milind M. Javle, Helena Verdaguer Mata, Filippo de Braud, Jörg Trojan, Jean-Luc Raoul +15 more

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting

JGH Open(2022)10.1002/jgh3.12691

N/A

0.330DataRank · unranked

8 citations

Manabu Morimoto, Makoto Ueno, Kousuke Kubota, Haruki Uojima, Hisashi Hidaka +12 more

Policy recommendations for promoting nuclear medicine therapy in Japan 2025, from the Working Group for promoting nuclear medicine therapy of the Japan Society of Clinical Oncology

International Journal of Clinical Oncology(2025)10.1007/s10147-025-02858-3

N/A

0.208DataRank · unranked

3 citations

Hideaki Miyake, Anri Inaki, Shoko Takano, Yasutoshi Kuboki, Takashi Mizowaki +11 more